Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 94, Issue 3, 2016, Pages 580-587

  Brade, Anthony M ^a,b   Ng, Sylvia ^a,b   Brierley, James ^a,b   Kim, John ^a,b   Dinniwell, Robert ^a,b   Ringash, Jolie ^a,b   Wong, Rebecca R ^a,b   Cho, Charles ^c   Knox, Jennifer ^a   Dawson, Laura A ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Southlake Regional Cancer Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER; PATIENT MONITORING; RADIOTHERAPY; TOXICITY;

BOWEL OBSTRUCTION; DOSE LIMITING TOXICITY; EASTERN COOPERATIVE ONCOLOGY GROUP; HEPATOCELLULAR CARCINOMA; METHODS AND MATERIALS; OVERALL SURVIVAL; PORTAL VEIN INVASIONS; STEREOTACTIC BODY RADIATION THERAPY;

PATIENT TREATMENT;

LIVER ENZYME; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD PUGH SCORE; CLINICAL ARTICLE; COHORT ANALYSIS; CONFUSION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPONATREMIA; INTESTINAL BLEEDING; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER WEIGHT; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORNING DOSAGE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STEREOTACTIC BODY RADIATION THERAPY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; INTESTINE; LIVER; LIVER NEOPLASMS; MALE; PROCEDURES; RADIATION RESPONSE; RADIOSURGERY; RADIOTHERAPY DOSAGE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DOSE FRACTIONATION; FEMALE; HUMANS; INTESTINES; LIVER; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIOSURGERY; RADIOTHERAPY DOSAGE;

EID: 84963737860     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.11.048     Document Type: Article

References (17)

1. M.M. Center, and A. Jemal International trends in liver cancer incidence rates Cancer Epidemiol Biomarkers Prev 20 2011 2362 2368
2. R. Siegel, J. Ma, Z. Zou, and et al. Cancer Statistics, 2014 CA Cancer J Clin 64 2014 9 29
3. A. Bujold, J. Sykes, J. Kim, and et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma J Clin Oncol 31 2013 1631 1639
4. H.R. Cardenes, T.R. Price, S.M. Perkins, and et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma Clin Transl Oncol 12 2010 218 225
5. B.O. Choi, I.B. Choi, H.S. Jang, and et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: Preliminary analysis BMC Cancer 8 2008 351
6. Q. Li, Y. Hu, M. Xi, and et al. Sorafenib modulates the radiosensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner BMC Cancer 12 2012 485
7. J. Llovet, S. Ricci, J. Mazzaferro, and et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
8. S.H. Son, B.O. Choi, M.R. Ryu, and et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: DOSE-volumetric parameters predicting the hepatic complication Int J Radiat Oncol Biol Phys 78 2010 1073 1080
9. M. Lee, J. Kim, R. Dinniwell, and et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases J Clin Oncol 27 2009 1585 1591
10. C.H. Crane, L.M. Ellis, J.L. Abbruzzese, and et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer J Clin Oncol 24 2006 1145 1151
11. T. Inoue, H. Kinoshita, and Y. Komai Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma World J Surg Oncol 10 2012 167
12. N. Peters, D. Richel, J. Verhoeff, and et al. Bowel perforation after radiotherapy in a patient receiving sorafenib J Clin Oncol 26 2008 2405 2406
13. B.M. Barney, S.N. Markovic, N.N. Laack, and et al. Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT) Int J Radiat Oncol Biol Phys 87 2013 73 80
14. S.W. Chen, L.C. Lin, Y.C. Kuo, and et al. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellularcarcinoma Int J Radiat Oncol Biol Phys 88 2014 1041 1047
15. W. Yu, K. Gu, Z. Yu, and et al. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo Cancer Lett 329 2013 109 117
16. A. Horgan, L. Dawson, A. Swaminanth, and et al. Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma J Gastrointest Cancer 43 2012 344 348
17. C.H. Hsieh, K.S. Jeng, C.C. Lin, and et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma Clin Drug Investig 29 2009 65 71